Drug intelligence / Profile preview

GQ1018

Development stage: Preclinical
Lead developer: GeneQuantum Biosciences
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GQ1018 (also known as GR1018) is an antibody-drug conjugate (ADC) being developed by GeneQuantum Healthcare for the treatment of oncology indications. The drug is engineered using GeneQuantum's proprietary intelligent Ligase Dependent Conjugation (iLDC) and iGDC platforms, which facilitate enzymatic site-specific conjugation to produce highly homogeneous ADCs with improved stability and therapeutic index. While the specific biological target, payload, and linker chemistry remain undisclosed, the candidate is part of a pipeline of "best-in-class" ADCs intended for various solid tumors. It is currently in the pre-clinical stage of development.

Beyond the preview

Go deeper on GQ1018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GQ1018.

Explore the full profile